Compare AR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AR | CYTK |
|---|---|---|
| Founded | 2002 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.0B |
| IPO Year | 2013 | 2004 |
| Metric | AR | CYTK |
|---|---|---|
| Price | $32.16 | $64.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 16 |
| Target Price | $44.35 | ★ $82.38 |
| AVG Volume (30 Days) | ★ 5.2M | 2.1M |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $5,007,754,000.00 | $87,211,000.00 |
| Revenue This Year | $24.23 | $346.43 |
| Revenue Next Year | $20.43 | $57.69 |
| P/E Ratio | $17.59 | ★ N/A |
| Revenue Growth | 17.21 | ★ 2609.26 |
| 52 Week Low | $29.10 | $29.31 |
| 52 Week High | $44.02 | $70.98 |
| Indicator | AR | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 37.80 | 53.27 |
| Support Level | $31.59 | $58.85 |
| Resistance Level | $35.63 | $64.43 |
| Average True Range (ATR) | 1.05 | 2.85 |
| MACD | -0.26 | -0.02 |
| Stochastic Oscillator | 13.73 | 44.23 |
Antero Resources, based in Denver, explores for and produces natural gas and natural gas liquids in the United States and Canada. At the end of 2024, the company reported proven reserves of 17.9 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,424 million cubic feet of equivalent a day in 2024 at a ratio of 35% liquids and 65% natural gas.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.